Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia
-
Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya))
;
Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ;
Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ;
Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Doubek, Michael (University Hospital Brno (República Txeca)) ;
Foà, Robin (Sapienza University of Rome) ;
Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ;
Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ;
Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Parovichnikova, Elena (National Research Center for Hematology, Moscow) ;
Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Schoonen, Marieke (Amgen Ltd, London) ;
Stieglmaier, Julia M. (Amgen GmBH, Munich) ;
Zugmaier, Gerhard (Amgen GmBH, Munich) ;
Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ;
Universitat Autònoma de Barcelona
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
